Skip to main content

Table 3B Clinical benefit achieved from subsequent lines of endocrine therapy in patients with clinical benefit to 1st line endocrine therapy

From: "Resurrection of clinical efficacy" after resistance to endocrine therapy in metastatic breast cancer

Lines of Endocrine therapy

2 nd line

3 rd line

4 th line

N

68

23

5

N of CB (%)

47 (69.1)

10 (43.5)

1(20.0)

Median DOR with CB (months)

12.0+(7–81)

11.0 (8–32)

15.0

N still receiving treatment

17

0

0

  1. + = including patients who are still on treatment, therefore would have additional duration of response on a later analysis; CB = Clinical Benefit; DOR = Duration of Response